Halbit F Cream is formulated with Halobetasol 0.05% w/w and Fusidic Acid 2% w/w, providing a dual-action therapy for inflammatory and bacterial skin conditions. Halobetasol, a potent corticosteroid, effectively reduces redness, swelling, and itching, while Fusidic Acid acts as a topical antibiotic, combating bacterial infections commonly associated with skin inflammation.
The combination ensures rapid relief from eczema, dermatitis, psoriasis, and secondary bacterial infections, offering both anti-inflammatory and antimicrobial benefits in a single formulation. Its optimized concentration makes it suitable for dermatological prescription use while minimizing potential side effects.
Belonging to the dermatology segment, Halbit F Cream is in high demand among dermatologists, hospitals, clinics, and PCD pharma franchise networks. Its proven efficacy, safe topical application, and dual-purpose action make it a trusted product for managing complex skin conditions.
For PCD franchise and B2B partners, Halbit F Cream presents a high-demand, profitable opportunity. Its combination of anti-inflammatory and antibacterial effects, strong clinical acceptance, and consistent prescription demand ensure excellent business growth, attractive margins, and a competitive edge in both domestic and export dermatology markets.